WBD Board Endorses $31 Cash Bid, Raising Stakes in Contested M&A Battle

What happened

Warner Bros. Discovery's board has backed a revised $31-per-share all-cash bid from PSKY, citing stronger terms and added deal protections, as reported by Zacks. This move unfolds within a complex M&A environment where Netflix has a signed $27.75 all-cash agreement and Paramount previously offered $30, per the DeepValue report. The report notes that WBD's stock trades above the Netflix deal price, making competitive bidding crucial for returns, with the bull scenario implying $30 from higher offers. Board support suggests a strategic shift to secure superior terms, potentially addressing activist pressures and timeline risks highlighted in filings. However, investors must critically assess whether this bid offers tangible improvements over existing proposals and can overcome regulatory and financing hurdles documented in the 10-Q.

Implication

This development could drive short-term stock appreciation, as the $31 bid represents a premium over Netflix's $27.75 offer, aligning with the bull case in the DeepValue report. However, the report emphasizes that deal completion depends on timely shareholder votes by April 2026 and antitrust clearance, with delays risking a drop to the $22 bear case. Financing constraints, such as the Bridge Loan Facility refinancing due by December 2026, add pressure if the process extends, as outlined in SEC filings. Enhanced deal protections may reduce termination risks, but investors must verify PSKY's funding credibility and regulatory readiness beyond board optimism. Given the stock's current level near $28, which exceeds the Netflix deal floor, entering now lacks a margin of safety, reinforcing the report's 'WAIT' rating for better entry points or concrete milestones.

Thesis delta

The endorsement of a $31 bid shifts the thesis by increasing the probability of the bull scenario, where competitive pressure drives prices above $27.75, potentially raising the base implied value. However, the core thesis remains unchanged: with the stock above deal value, investors should still wait for a discount to $27.75 or clear regulatory catalysts, as execution risks and financing uncertainties persist.